FILTER
FILTERED INTERVIEW RESULTS
Mohal Sarabhai
CEO, ASENCE PHARMA PRIVATE LIMITED
"We are working closely with our US partners to bring one of the most affordable point of care testing (POCT) devices to the market that will be saliva-based to provide the accuracy of a PCR machine on a POC device."
Sudheendra Kulkarni
CEO, SOUTH ASIA & ASEAN FERRING PHARMACEUTICALS
Ferring is a global biopharmaceutical company based in Switzerland that has one of the most comprehensive footprints in India.
Milind Antani and Darren Punnen
LEAD - PHARMA, HEALTHCARE, MEDICAL SERVICE AND DIGITAL HEALTH PRACTICE & LEADER - PHARMA AND LIFE SCIENCES PRACTICE, NISHITH DESAI ASSOCIATES (NDA)
Practice, Nishith Desai Associates (NDA) speak about legal developments relating to India’s life sciences industry
Lakshmi Prasanna Chundu
DIRECTOR - REGULATORY AFFAIRS, THE PHARMACEUTICAL EXPORT PROMOTION COUNCIL OF INDIA (PHARMEXCIL)
Pharmexcil explains how the agency is promoting India’s life sciences exports, which aim to reach US$40 billion in five years.
Daara Patel
SECRETARY GENERAL, INDIAN DRUG MANUFACTURERS’ ASSOCIATION (IDMA)
"Today, India's pharmaceutical sector is a US$50 billion industry and we anticipate it growing to at least US$150 billion in less than a decade."
Roma Shah & Komal Doshi
CEO & DIRECTOR, EASTMEN CHEMICALS
Eastmen Chemicals is set on increasing its market beyond India.
Ravi Udaya Bhaskar
DIRECTOR GENERAL, PHARMEXCIL
India’s Pharmexcil discusses developments in the country’s pharmaceuticals segment.
Dr. Sharvil Patel
MANAGING DIRECTOR, ZYDUS CADILA
Zydus Cadila ranks fourth in the Indian pharmaceutical industry, with a strong global presence in the U.S., Europe, Latin America and South Africa, alongside 25 other emerging markets worldwide.
Dr. Kunal Saxena
MANAGING DIRECTOR, RUSAN PHARMA
Rusan Pharma is a fully integrated pharmaceutical company specializing in the treatment of addiction and pain management.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
